Ocular Therapeutix (OCUL) News Today $8.80 +0.27 (+3.17%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$8.30 -0.51 (-5.74%) As of 05:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Voya Investment Management LLC Has $3.17 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Voya Investment Management LLC raised its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 35.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 371,235 shares of the biopharmaceutical company's stock after buying an additional 97,6May 5 at 4:23 AM | marketbeat.comWells Fargo & Company MN Has $634,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Wells Fargo & Company MN lessened its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 83.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,208 shares of the biopharmaceutMay 5 at 3:15 AM | marketbeat.comAcuta Capital Partners LLC Has $9.49 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Acuta Capital Partners LLC lessened its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 6.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,111,071 shares of the biopharmaceutical company's stock after seMay 4 at 7:11 AM | marketbeat.comRaymond James Financial Inc. Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Raymond James Financial Inc. purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 201,623 shares of the biopharmaceutical company's stoMay 4 at 3:28 AM | marketbeat.comOcular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 3 at 5:56 PM | finance.yahoo.comOcular Therapeutix (OCUL) Projected to Post Quarterly Earnings on MondayMay 3 at 2:22 AM | americanbankingnews.comOcular Therapeutix Q1 2025 Earnings PreviewMay 2 at 2:42 PM | msn.comBarclays PLC Reduces Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Barclays PLC lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 35.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 331,242 shares of the biopharmaceutical company's stock after selling 180,280 sMay 2 at 3:43 AM | marketbeat.comOcular Therapeutix (OCUL) Projected to Post Quarterly Earnings on TuesdayOcular Therapeutix (NASDAQ:OCUL) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-ocular-therapeutix-inc-stock/)May 1, 2025 | marketbeat.comOcular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025April 30, 2025 | seekingalpha.comOcular Therapeutix (NASDAQ:OCUL) Trading Up 5.4% - What's Next?Ocular Therapeutix (NASDAQ:OCUL) Trading 5.4% Higher - Here's What HappenedApril 30, 2025 | marketbeat.comNantahala Capital Management LLC Sells 262,272 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Nantahala Capital Management LLC decreased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 37.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 437,728 shares of the bApril 30, 2025 | marketbeat.comOcular Therapeutix™ to Participate in Upcoming Investor and Scientific ConferencesApril 29, 2025 | tmcnet.comAnalysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Target Price at $16.38April 29, 2025 | americanbankingnews.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. decreased its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 4.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,600,000 shares of the biopharmaceuticApril 28, 2025 | marketbeat.comJPMorgan Chase & Co. Has $1.62 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)JPMorgan Chase & Co. grew its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 123.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 189,295 shares of the biopharmaceutical company's stock after acquiring an additioApril 28, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have been given an average rating of "Moderate Buy" by the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eight have iApril 28, 2025 | marketbeat.comInvesco Ltd. Acquires 134,573 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Invesco Ltd. lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 17.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 890,046 shares of the biopharmaceutical company's stock after acquiring an additional 134,573 shares duApril 27, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Price Up 5.8% - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Shares Up 5.8% - Here's What HappenedApril 23, 2025 | marketbeat.comGeode Capital Management LLC Has $27.64 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Geode Capital Management LLC cut its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,236,312 shares of the biopharmaceutical company's stApril 20, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Down 4.9% - What's Next?Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 4.9% - Should You Sell?April 18, 2025 | marketbeat.comWhat is William Blair's Forecast for OCUL Q1 Earnings?Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities research analysts at William Blair issued their Q1 2025 earnings estimates for shares of Ocular Therapeutix in a research report issued on Tuesday, April 8th. William Blair analyst L. Hanbury-Brown forecasts that the biopharmaceuticaApril 13, 2025 | marketbeat.comVanguard Group Inc. Purchases 99,730 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Vanguard Group Inc. lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,483,913 shares of the biopApril 13, 2025 | marketbeat.comOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | globenewswire.comWilliam Blair starts Ocular Therapeutix stock with OutperformApril 10, 2025 | uk.investing.comOcular Therapeutix (NASDAQ:OCUL) Earns Outperform Rating from Analysts at William BlairWilliam Blair assumed coverage on Ocular Therapeutix in a research note on Tuesday. They issued an "outperform" rating on the stock.April 10, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday.April 10, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform RecommendationApril 9, 2025 | msn.comOcular Therapeutix (OCUL) Receives a Buy from NeedhamApril 9, 2025 | markets.businessinsider.comOcular Therapeutix initiated with an Outperform at William BlairApril 8, 2025 | msn.comNottingham Advisors Inc. Has $835,000 Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Nottingham Advisors Inc. lowered its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 47.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,828 shares of the biopharmaceuticalApril 5, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 4.9% - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Trading 4.9% Higher - Here's What HappenedApril 4, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Trading Down 5.8% - Time to Sell?Ocular Therapeutix (NASDAQ:OCUL) Trading Down 5.8% - What's Next?April 3, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $1.72 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Raymond James Financial Inc. acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 201,623 shares of the biopharmaceApril 2, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating onApril 2, 2025 | marketbeat.comOcular Therapeutix™ to Participate in Two Investor Conferences in AprilMarch 31, 2025 | globenewswire.comArtisan Partners Limited Partnership Purchases 278,610 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Artisan Partners Limited Partnership raised its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 26.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,334,702 shares of the biopharmaceutical company'sMarch 30, 2025 | marketbeat.comOcular Therapeutix added to Analyst Current Favorites list at Raymond JamesMarch 27, 2025 | markets.businessinsider.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Raised by Rosalind Advisors Inc.Rosalind Advisors Inc. lifted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 27.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,128,700 shares of the biopharmaceutical company's stock after purchasing aMarch 23, 2025 | marketbeat.comVictory Capital Management Inc. Boosts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Victory Capital Management Inc. boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 300.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,871 shares of the biopharmaceMarch 22, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Up - What's Next?Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up - What's Next?March 19, 2025 | marketbeat.comRoyal Bank of Canada Begins Coverage on Ocular Therapeutix (NASDAQ:OCUL)Royal Bank of Canada began coverage on Ocular Therapeutix in a research report on Tuesday. They set an "outperform" rating and a $17.00 price objective for the company.March 19, 2025 | marketbeat.com3OCUL : What 4 Analyst Ratings Have To Say About Ocular TherapeutixMarch 18, 2025 | benzinga.comRBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform RecommendationMarch 18, 2025 | msn.comOcular Therapeutix (OCUL) Gets a Buy from RBC CapitalMarch 18, 2025 | markets.businessinsider.comOcular Therapeutix initiated with an Outperform at RBC CapitalMarch 18, 2025 | markets.businessinsider.comWhy Ocular Therapeutix Was Bumping Higher This WeekMarch 14, 2025 | fool.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 9.7% - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 9.7% - Here's WhyMarch 12, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from Analysts at Needham & Company LLCNeedham & Company LLC assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday. They set a "buy" rating and a $15.00 target price for the company.March 12, 2025 | marketbeat.comOcular Therapeutix initiated with a Buy at NeedhamMarch 11, 2025 | markets.businessinsider.com Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUL Media Mentions By Week OCUL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUL News Sentiment▼0.860.73▲Average Medical News Sentiment OCUL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUL Articles This Week▼154▲OCUL Articles Average Week Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GRFS News Today CYTK News Today KRYS News Today ELAN News Today PCVX News Today RYTM News Today PTCT News Today RNA News Today ZLAB News Today RARE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUL) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCUL Stock Free OCUL Stock Alerts